Shorts

Alexander Z. Wei, MD, discussed strategies clinicians use to reduce the burden of surgery and preserve quality of life among patients with advanced urothelial cancers.

1:17

Highlighting Bladder Preservation Among Vulnerable MIBC Populations

2 months ago

Alexander Z. Wei, MD

0:46

Why mRNA Vaccines Change the Melanoma Game

2 months ago

Jamin C. Morrison, MD

0:45

Comparing HIFU To Surgery and SBRT in Localized Prostate Cancer

2 months ago

Mina Fam, MD

Benjamin Cooper, MD, spoke with CancerNetwork® about the mechanism of JNJ-1900, an investigational nanoparticle radioenhancer, as a treatment for patients with unresectable stage III non–small cell lung cancer as part of the phase 2 CONVERGE trial (NCT06667908).

0:51

Novel Radioenhancer May Help Prevent Disease Recurrence in Stage III NSCLC

2 months ago

Benjamin Cooper, MD

1:00

Why Are Younger Women Getting Diagnosed With Breast Cancer?

2 months ago

Shari B. Goldfarb, MD

In a conversation with CancerNetwork®, Nicole Lamanna, MD, discussed the potential role of minimal residual disease (MRD) as a tool for informing treatment strategies in chronic lymphocytic leukemia (CLL) management.

0:54

Can MRD Influence Therapy Duration in Chronic Lymphocytic Leukemia?

2 months ago

Nicole Lamanna, MD

In a discussion with CancerNetwork®, Nicolas Girard, MD, PhD, highlighted findings from the PALOMA-2 study (NCT05498428) that he and colleagues presented at the 2026 European Lung Cancer Congress.

0:53

PALOMA-2 Shows Benefits of Subcutaneous Amivantamab in EGFR+ NSCLC

2 months ago

Nicolas Girard, MD, PhD

Jeff P. Sharman, MD, identified ways to help expand access to bispecific antibodies among patients with diffuse large B-cell lymphoma.

1:25

Overcoming Institutional Barriers to Bispecific Antibody Access in DLBCL

2 months ago

Jeff P. Sharman, MD

Karie Runcie, MD, provided next steps for improving outcomes in genitourinary cancers, specifically related to kidney cancer.

0:38

Leveraging Neoadjuvant Strategies to Bolster Cure Rates in Kidney Cancer

2 months ago

Karie Danielle Keera Runcie, MD

A recent study that found 10.6% of patients developed a new mental health disorder within 1 year of their cancer diagnosis.

1:16

What New Tools Can Improve Mental Health Screening in Cancer Care?

2 months ago

Julian C. Hong, MD, MS

Karie Runcie, MD, highlighted research she conducted as part of the phase 2 Cyto-KIK trial, a single-arm study assessing cabozantinib and nivolumab in metastatic kidney cancer prior to cytoreductive nephrectomy.

0:49

Cabozantinib Combo Displays Feasibility in Metastatic Kidney Cancer Group

2 months ago

Karie Danielle Keera Runcie, MD

Oxybutynin offered comparable ‘speed-to-relief’ vs comparators among patients experiencing hot flashes while on androgen deprivation therapy for prostate cancer, according to Bradley J. Stish, MD.

0:44

Offering Rapid Relief of Treatment-Emergent Hot Flashes in Prostate Cancer

2 months ago

Bradley J. Stish, MD

$Following the FDA approval of teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients with relapsed/refractory multiple myeloma, María-Victoria Mateos, MD, PhD, spoke with CancerNetwork® about how findings from the phase 3 MajesTEC-3 trial (NCT05083169) support the regimen’s clinical utility.$

0:45

Teclistamab/Daratumumab: An Exciting Combination in R/R Multiple Myeloma

2 months ago

Maria-Victoria Mateos, MD, PhD